Today's Top Story

U.K.’s life sciences sector dodges Labour bullet, concerns about relationship with EU remain

British biotech may have dodged a bullet with the Conservative victory, but the sector’s long-term fate, like that of the country, remains uncertain in the wake of an election that will result in a ...

Company News

FDA approves Amarin’s Vascepa to reduce CV risk in narrower population

FDA approved Amarin’s Vascepa for cardiovascular risk reduction Friday, though the label is slightly more restrictive than what the company had been aiming for. Shares of Amarin Corp. plc ...

Novartis gains CHMP support for Eylea competitor in wet AMD

EMA's CHMP issued a positive opinion for Novartis’ Beovu brolucizumab in its December roundup of opinions, none of which were negative. The agency backed an MAA from Novartis AG (NYSE:NVS; SIX:NOVN) ...

CVS program seeks to encourage genetic testing of cancer patients

CVS is addressing the disconnect between availability of targeted cancer therapies and limited access to genetic tests through a precision medicine program that encourages next generation sequencing ...

Dec. 13 Company Quick Takes: Horizon, Intercept, Imfinzi, Evenity and Numab-3SBio

FDA panel backs Horizon's eye disease candidate FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously Friday that the benefits of teprotumumab to treat active thyroid eye ...

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio ...

Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

Biogen is terminating development of gosuranemab to treat primary tauopathies following a mid-stage clinical failure, but the move won’t scuttle a Phase II trial of the anti-tau mAb to treat ...

Financial News

NanoDimension backs sight-restoring therapy developer Arctos in series A

Newly launched Arctos will use CHF8 million in series A money to conduct preclinical work on a vector-delivered technology it believes can restore eyesight in patients whose retinal cells have ...

Politics & Policy

Trade deal could advance Beijing’s plans to improve pharma IP protections

A long-awaited U.S.-China trade agreement could help China make progress on an initiative to improve patent protections for pharmaceuticals, which have seen little improvement since early plans were ...

BioCentury Extra ISSN 2642-3812